NOVALIQ GmbH, headquartered in Heidelberg, is a biopharmaceutical company developing water-free therapeutics based on its proprietary EyeSol® technology with a focus on ophthalmology. Prescription products include CyclASol® and NOVO3 for dry eye treatment, and the CE‑registered medical devices NovaTears® and NovaTears®+Omega3 are marketed via distribution partners. NOVALIQ generates revenue primarily through licensing and partner commercialization and maintains three U.S. subsidiaries to support development and commercialization. As of 31 December 2024 the company employed 27 people and runs an R&D-focused strategy supported by an extensive patent portfolio (45 patent families, 202 granted patents).
Die Verwertung semifluorierter Alkane im medizinischen und pharmazeutischen Bereich.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 701863 (as of 22 August 2026)
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 701863 (as of 22 August 2026)
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 701863 (as of 22 August 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 701863 (as of 22 August 2026)
Sign in to view detailed salary and cost trends.
